ACAM 3000 MVA at Harvard Medical School

NCT ID: NCT00133575

Last Updated: 2015-01-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 72 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-10-31
• Study Completion Date: 2008-04-30

Brief Summary

The purpose of this study is to assess the safety of an experimental smallpox vaccine (MVA: Modified Vaccinia Ankara) and to compare the body's immune (system that fights disease) response to this vaccine. Participants will be assigned to 1 of 6 study groups. Each group will include 12 subjects, 10 will receive the modified smallpox vaccine and two will receive placebo, an inactive substance. The vaccine will be administered in 1 of 3 ways: under the skin; in the muscle; or between the muscle and the skin. Groups A and B will receive Dryvax® 6-15 months after the initial MVA vaccine; groups C, D, E, and F will receive Dryvax® 6 months after the initial MVA vaccine. Study procedures will include documenting side effects for 14 days after each vaccination, electrocardiogram (picture of the hearts activity) and blood samples. Participants will be involved in study related procedures for up to 18 months.

Detailed Description

The emergence of smallpox as a potential agent of bioterrorism has heightened concern about the vulnerability of the population to infection with this agent, and has led to proposals to undertake large scale smallpox immunization of military personnel and "first responders" in the United States, including certain health care workers. A particularly promising vaccine approach to the development of an effective, yet less reactogenic vaccine to smallpox is the use of Modified Vaccinia Ankara (MVA) as a vaccine. Despite the established efficacy of smallpox vaccination, the parameters of protective immunity against smallpox infection are incompletely understood. This is a phase I/II trial to be conducted under a placebo controlled double-blind, randomized allocation of study product. The purpose of this study is to assess the safety and immunogenicity of ACAM 3000 MVA in healthy vaccinia-naïve adult subjects. Participants will include 72 healthy, male or female, from the Boston metropolitan area. Six dose regimens will be studied initially: 10^6 or 10^7 tissue culture infectious dose 50 (TCID50) administered intradermally and 10^7 or 10^8 TCID50 administered intramuscularly or subcutaneously as 2 immunizations 1 month apart. Each arm will be comprised of 12 subjects, 10 of whom will receive ACAM3000 MVA and 2 of whom will receive placebo. A subsequent vaccinia vaccination will be offered to all patients. Consenting participants in Groups A and B will receive the vaccinia (Dryvax®) inoculation between 6 and 15 months after the initial MVA / placebo vaccination. Consenting participants in groups C, D, E and F will receive the Dryvax® inoculation approximately 6 months after the initial MVA / placebo vaccination, coinciding with planned visit 13. Assessment of safety will be carried out by observation and measurement of acute clinical and laboratory evidence of reactions or toxicity; including clinical, electrocardiographic or laboratory evidence of myopericarditis. Assessment of immunogenicity will be carried out by the measurement of humoral and cell-mediated immune response to ACAM 3000 MVA and vaccinia, performed on blood samples obtained at various times prior to and after immunization over the one year period of the study. Response to vaccinia will be assessed clinically (effect on a "take") and the results will be correlated with immune responses to MVA. Subjects will be followed for reactogenicity. Clinical assessments and blood samples will be obtained sequentially for immunogenicity determinations.

Conditions

Smallpox

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: DOUBLE

Study Groups

Group E: ACAM3000 MVA 10^7 ID

10 subjects to receive ACAM3000 MVA dose 10\^7 TCID50 via intradermal route on days 0 and 28; 2 subjects to receive placebo via intradermal route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10\^8 pfu/ml.

Group Type: EXPERIMENTAL

Placebo

Intervention Type: OTHER

Sterile saline (0.9%) volume of 0.5 ml intradermally in the deltoid.

MVA Smallpox Vaccine

Intervention Type: BIOLOGICAL

MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10\^6 or 10\^7 TCID50 intradermally (ID).

Live vaccinia virus vaccine

Intervention Type: BIOLOGICAL

Dryvax® smallpox vaccine administered at approximately day 180, dosage 10\^8 pfu/ml.

Group F: ACAM3000 MVA 10^8 IM

10 subjects to receive ACAM3000 MVA dose 10\^8 TCID50 via intramuscular route on days 0 and 28; 2 subjects to receive placebo via intramuscular route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10\^8 pfu/ml.

Group Type: EXPERIMENTAL

MVA Smallpox Vaccine

Intervention Type: BIOLOGICAL

MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10\^7 or 10\^8 TCID50 intramuscularly (IM).

Live vaccinia virus vaccine

Intervention Type: BIOLOGICAL

Dryvax® smallpox vaccine administered at approximately day 180, dosage 10\^8 pfu/ml.

Placebo

Intervention Type: OTHER

Sterile saline (0.9%) volume of 0.5 ml intramuscularly in the deltoid.

Group D: ACAM3000 MVA 10^8 SC

10 subjects to receive ACAM3000 MVA dose 10\^8 TCID50 via subcutaneous route on days 0 and 28; 2 subjects to receive placebo via subcutaneous route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10\^8 pfu/ml.

Group Type: EXPERIMENTAL

MVA Smallpox Vaccine

Intervention Type: BIOLOGICAL

MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10\^7 or 10\^8 TCID50 subcutaneously (SC).

Placebo

Intervention Type: OTHER

Sterile saline (0.9%) volume of 0.5 ml subcutaneously in the deltoid.

Live vaccinia virus vaccine

Intervention Type: BIOLOGICAL

Dryvax® smallpox vaccine administered at approximately day 180, dosage 10\^8 pfu/ml.

Group B: ACAM3000 MVA 10^7 IM

10 subjects to receive ACAM3000 MVA dose 10\^7 TCID50 via intramuscular route on days 0 and 28; 2 subjects to receive placebo via intramuscular route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10\^8 pfu/ml.

Group Type: EXPERIMENTAL

MVA Smallpox Vaccine

Intervention Type: BIOLOGICAL

MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10\^7 or 10\^8 TCID50 intramuscularly (IM).

Live vaccinia virus vaccine

Intervention Type: BIOLOGICAL

Dryvax® smallpox vaccine administered at approximately day 180, dosage 10\^8 pfu/ml.

Placebo

Intervention Type: OTHER

Sterile saline (0.9%) volume of 0.5 ml intramuscularly in the deltoid.

Group A: ACAM3000 MVA 10^6 ID

10 subjects to receive ACAM3000 MVA dose 10\^6 tissue culture infectious dose 50 (TCID50) via intradermal (ID) route on days 0 and 28; 2 subjects to receive placebo via intradermal route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10\^8 pfu/ml.

Group Type: EXPERIMENTAL

Placebo

Intervention Type: OTHER

Sterile saline (0.9%) volume of 0.5 ml intradermally in the deltoid.

MVA Smallpox Vaccine

Intervention Type: BIOLOGICAL

MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10\^6 or 10\^7 TCID50 intradermally (ID).

Live vaccinia virus vaccine

Intervention Type: BIOLOGICAL

Dryvax® smallpox vaccine administered at approximately day 180, dosage 10\^8 pfu/ml.

Group C: ACAM3000 MVA 10^7 SC

10 subjects to receive ACAM3000 MVA dose 10\^7 TCID50 via subcutaneous (SC) route on days 0 and 28; 2 subjects to receive placebo via subcutaneous route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10\^8 pfu/ml.

Group Type: EXPERIMENTAL

MVA Smallpox Vaccine

Intervention Type: BIOLOGICAL

MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10\^7 or 10\^8 TCID50 subcutaneously (SC).

Placebo

Intervention Type: OTHER

Sterile saline (0.9%) volume of 0.5 ml subcutaneously in the deltoid.

Live vaccinia virus vaccine

Intervention Type: BIOLOGICAL

Dryvax® smallpox vaccine administered at approximately day 180, dosage 10\^8 pfu/ml.

Interventions

MVA Smallpox Vaccine

MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10\^7 or 10\^8 TCID50 intramuscularly (IM).

Intervention Type: BIOLOGICAL

MVA Smallpox Vaccine

MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10\^7 or 10\^8 TCID50 subcutaneously (SC).

Intervention Type: BIOLOGICAL

Placebo

Sterile saline (0.9%) volume of 0.5 ml intradermally in the deltoid.

Intervention Type: OTHER

Placebo

Sterile saline (0.9%) volume of 0.5 ml subcutaneously in the deltoid.

Intervention Type: OTHER

MVA Smallpox Vaccine

MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10\^6 or 10\^7 TCID50 intradermally (ID).

Intervention Type: BIOLOGICAL

Live vaccinia virus vaccine

Dryvax® smallpox vaccine administered at approximately day 180, dosage 10\^8 pfu/ml.

Intervention Type: BIOLOGICAL

Placebo

Sterile saline (0.9%) volume of 0.5 ml intramuscularly in the deltoid.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

General:

• Age: greater than or equal to 18 and born after 1971.
• Complete a written assessment of understanding prior to enrollment and verbalize understanding of all questions answered incorrectly.
• Informed consent: Be able, willing, and have signed the informed consent form.
• Health: Be in good general health without clinically significant medical history, physical examination findings, or clinically significant abnormal laboratory results. A clinically significant condition or process includes one or more of the following: a) A condition that is chronic or recurring and is life threatening b) A process that would affect the immune response c) A process that would require medication that affects the immune response d) A condition for which repeated injections or blood draws may pose additional risk to the participant e) A condition that requires active medical intervention or monitoring to avert grave danger to the participant's health or well-being f) A condition or process in which signs or symptoms could be confused with reactions to vaccine

Laboratory:

• Willing to have blood samples stored for future smallpox related research.
• Hematology and chemistries within institutional normal limits for age and sex for the following: hemoglobin, white blood cell (WBC)], serum creatinine, platelets, troponin, alanine aminotransferase (ALT) [within 1.25 under normal limits (ULN), aspartate aminotransferase (AST) (within 1.25 ULN), alkaline phos (within 1.25 ULN), total bilirubin (within 1.25 ULN).
• Negative for Hepatitis B surface antigen and Hepatitis C virus (HCV) antibodies [If HCV antibodies are positive, and negative for HCV by polymerase chain reaction (PCR), subject is eligible]
• Negative FDA-approved human immunodeficiency virus (HIV) blood test within 8 weeks prior to enrollment
• Normal urine dipstick or urinalysis:

1. Negative glucose, and

2. Negative or trace protein and negative or trace hemoglobin (if trace hemoglobin is present, a urinalysis is required to exclude participants with counts greater than the institutional normal range)

In addition to meeting ALL of the above criteria, FEMALE participants must meet BOTH of the following criteria:

• Negative serum or urine beta-human chorionic gonadotropin (HCG) pregnancy test performed within 24 hours prior to any vaccination.
• Reproductive status: A female participant either must:

1. not be of reproductive potential. Reproductive potential in women is defined as not having reached menopause (no menses for one year) or having undergone hysterectomy, bilateral oophorectomy, or tubal ligation.

2. be with a male partner(s) throughout the duration of the study who has undergone successful vasectomy (A vasectomy is considered successful if a woman reports that a male partner has (1) microscopic documentation of azospermia, or (2) a vasectomy more than 2 years ago with no resultant pregnancy despite sexual activity post-vasectomy.), or

3. agree to avoid pregnancy through alternative methods and agree to consistently use contraception for at least 21 days prior to enrollment until the last protocol visit. Contraception is defined as using one of the following methods:

i) condoms (male or female with or without a spermicide) ii) diaphragm or cervical cap with spermicide iii) intrauterine device (IUD) iv) hormone-based therapy, e.g., contraceptive pills, Norplant, or Depo-Provera

In addition to the above criteria, female participants must meet the following criteria prior to participating in Dryvax vaccination:

• Negative serum or urine beta-HCG pregnancy test performed within 24 hrs prior to vaccination.
• Comply with one of the following methods of contraception for at least 21 days prior to vaccination and at least 2 months post vaccination.

1. Hormonal contraception: such as implants, injectables, combined oral contraceptives

2. Not be of reproductive potential: this may be due to

i) Hysterectomy or tubal ligation ii) The participant is in a monogamous relationship with a male partner who has undergone successful vasectomy (Successful vasectomy as defined as microscopic documentation of azospermia or a vasectomy more than two years ago with no resultant pregnancy despite sexual activity post-vasectomy.) c) Sexual abstinence

Exclusion Criteria

• Prior vaccination with a vaccinia product. Determined by clinical evidence of scarification or self-reported history of vaccinia vaccination (such as in the United States military before 1991 or after 2003).
• Immunosuppressive medications within 168 days prior to initial study vaccine administration, e.g., oral/parenteral corticosteroids, and/or cytotoxic medications. Not excluded: A participant using any of the following is not excluded: corticosteroid nasal spray for allergic rhinitis; or topical corticosteroids as prescribed by a physician for an acute, uncomplicated dermatitis; or over the counter medications (including topical corticosteroids for an acute, uncomplicated dermatitis); use of rapidly tapered steroids for an acute isolated condition, which does not include asthma within 28 days prior to vaccine administration.
• Currently using corticosteroid eye drops.
• Receipt of blood products within 120 days prior to initial study vaccine administration.
• Receipt of immunoglobulin within 60 days prior to initial study vaccine administration.
• Receipt of live attenuated vaccines within 30 days prior to initial study vaccine administration.
• Receipt of investigational research agents within 30 days prior to initial study vaccine administration.
• Receipt of medically indicated subunit or killed vaccines, e.g., influenza, pneumococcal, or allergy treatment with antigen injections within 14 days prior to initial study vaccine administration.

Participant has a history of any of the following:

• Acute febrile illness on the day of vaccination.
• Eczema or atopic dermatitis (past or present).
• Chronic exfoliative skin condition.
• Acute skin disorders of large magnitude (greater than 2x2 centimeters), e.g., burns or lacerations.
• History or presence of skin cancer at vaccination site.
• Heart disease including history of a myocardial infarction (MI), angina, congestive heart failure (CHF), or pericardial pathology.
• Ten percent or greater risk of developing a myocardial infarction or coronary death within the next 10 years using the National Cholesterol Education Program's risk assessment tool (http://hin.nhlbi.nih.gov/atpiii/calculator.asp).

NOTE: This criterion applies only to subjects 20 years of age and older AND only if at least one of the following applies:

a) have smoked a cigarette in the past month, and/or b) have hypertension (defined as systolic blood pressure greater than 140 mm Hg) or are on antihypertensive medication, and/or c) have a family history of coronary heart disease in male first-degree relative (father or brother) less than 55 years of age or a female first-degree relative (mother or sister) less than 65 years of age.

• Household contacts/sexual contacts with, or frequent and/or prolonged exposure to any of the following:

a) Children less than 12 months of age b) Pregnant women or women who are breast feeding c) Individuals with a history of eczema or atopic dermatitis d) Individuals with chronic exfoliative skin disorders or skin disorders of large magnitude (greater than 2x2 centimeters) e) Individuals with an immunosuppressive disorder such as HIV infection, organ transplantation, or a condition requiring prolonged corticosteroid therapy

• Electrocardiogram (ECG) with clinically significant findings, or features that would interfere with the assessment of myo/pericarditis as determined by the consulting cardiologist, including any of the following: (1) Conduction disturbance (complete left or incomplete right bundle branch block or nonspecific intraventricular conduction disturbance with waves of ventricular activity of the heart traced on an ECG (QRS) greater than 120 millisecond (ms), atrioventricular (AV) block of any degree, or QTc prolongation (greater than 440 ms); (2) Repolarization (ST segment or T wave) abnormality; (3) Significant atrial or ventricular arrhythmia; (4) Frequent atrial or ventricular ectopy (e.g. frequent premature atrial contractions, 2 premature ventricular contractions in a row); (5) ST elevation consistent with ischemia; (6) Evidence of past or evolving myocardial infarction.
• Known or suspected allergy to any component of the vaccine or diluent.
• Allergy to eggs or blood products [including immunoglobulin (IgG) or vaccinia immunoglobulin].
• Serious adverse reactions to vaccines including anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema, and/or abdominal pain. Not excluded: A participant who had an adverse reaction to pertussis vaccine as a child is not excluded.
• Autoimmune disease.
• Immunodeficiency.
• Asthma that is unstable, e.g., use of oral or intravenous corticosteroids, hospitalization or intubation during the past 2 years a) Inhaled steroids are not permissible
• Diabetes mellitus type I or type II including cases controlled with diet alone. Not excluded: A participant with past gestational diabetes is not excluded.
• Bleeding disorder diagnosed by a doctor, e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions. Not excluded: A participant who states he/she has easy bruising or bleeding, but does not carry a formal diagnosis and has had intramuscular (IM) injections and blood draws without any adverse experience, is not excluded.
• Seizure disorder not excluded: A participant with a remote history (over 3 years ago) of seizure who has not required medications for over 3 years is not excluded if (a) the seizures were febrile seizures under the age of 2, or (b) secondary to alcohol withdrawal, or (c) if the seizure only occurred once.
• Asplenia. Any condition resulting in the absence or removal of the spleen.
• Psychiatric condition that precludes compliance with the protocol. Specifically excluded are persons with one or more of the following:

a) Psychoses within the past 5 years. b) Suicidal ideation occurring within 2 years prior to enrollment. Not excluded: A participant with a remote history (greater than 3 years) of a suicide attempt or suicide gesture is not excluded if the investigator finds the participant (a) to be of sound mental health; and (b) the suicide attempt was a well-defined, isolated event; and (c) the cause or inciting factor(s) no longer has relevance to the individual. A participant currently in therapy, due to a suicide attempt or gesture, or suicidal ideation, may be enrolled only when the participant's current therapist or health care provider provides documentation that the participant currently is not suicidal.

• Any medical, psychiatric, or social condition, or occupational or other responsibility that, in the judgment of the investigator, would interfere with, or serve as a contraindication to, protocol adherence or a participant's ability to give informed consent.
• Female participants: Participant is pregnant and/or breast-feeding.

-A history of the following:

1. Excessive scarring

2. Known or suspected allergy to any component of the vaccine or diluent including polymyxin B sulfate, dihydrostreptomycin sulfate, chlorotetracycline hydrochloride, neomycin, and phenol.

3. Known allergy to cidofovir or probenecid -Abnormal renal function:

a) A calculated creatinine clearance less than 80 mL/min based on the following formulas: i) Males: [(140 - age in years) X weight in kilograms (kg)]/(72 X serum creatinine) ii) Females: 0.85 X [(140 - age in years) X weight in kg]/(72 X serum creatinine)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 38 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Brigham and Women's Hospital - Infectious Diseases

Boston, Massachusetts, United States

Countries

United States

References

Seaman MS, Wilck MB, Baden LR, Walsh SR, Grandpre LE, Devoy C, Giri A, Noble LC, Kleinjan JA, Stevenson KE, Kim HT, Dolin R. Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax. J Infect Dis. 2010 May 1;201(9):1353-60. doi: 10.1086/651560.

Reference Type: RESULT

PMID: 20350190 (View on PubMed)

Wilck MB, Seaman MS, Baden LR, Walsh SR, Grandpre LE, Devoy C, Giri A, Kleinjan JA, Noble LC, Stevenson KE, Kim HT, Dolin R. Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration. J Infect Dis. 2010 May 1;201(9):1361-70. doi: 10.1086/651561.

Reference Type: RESULT

PMID: 20350191 (View on PubMed)

Other Identifiers

5U54AI057159-10

Identifier Type: NIH

Identifier Source: secondary_id

View Link

05-0010

Identifier Type: -

Identifier Source: org_study_id